<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02499302</url>
  </required_header>
  <id_info>
    <org_study_id>CEBA part 2</org_study_id>
    <nct_id>NCT02499302</nct_id>
  </id_info>
  <brief_title>Mental Training for CFS Following EBV Infection in Adolescents</brief_title>
  <official_title>Mental Training for Chronic Fatigue Syndrome (CFS/ME) Following EBV Infection in Adolescents: A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Akershus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general aim of this study is to investigate the effect of an individually tailored mental&#xD;
      training program in adolescents developing chronic fatigue syndrome (CFS) after an acute&#xD;
      Epstein Barr-virus (EBV) infection. Endpoints include physical activity (primary endpoint),&#xD;
      symptoms (fatigue, pain, insomnia), cognitive function (executive functions) and markers of&#xD;
      disease mechanisms (autonomic, endocrine, and immune responses).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      EBV-infection is a well-known trigger of CFS. A closely related research project (Chronic&#xD;
      fatigue following acute Epstein-Barr virus infection in Adolescents; ClinicalTrials&#xD;
      ID:NCT02335437) is a combined prospective and cross-sectional study of 200 adolescents&#xD;
      suffering from acute EBV infection. The primary aim of that study is to identify factors that&#xD;
      predispose to CFS 6 months after the acute infection. Thus, that project will provide a&#xD;
      sample of thoroughly characterized CFS patients, all having the same precipitation factor&#xD;
      (EBV-infection).&#xD;
&#xD;
      The present project is an intervention trial in the subgroup of patients that actually did&#xD;
      develop CFS 6 months after the acute EBV infection. Patients will be randomised 1:1 to either&#xD;
      a mental training program (10 sessions) combining elements from cognitive behavioral therapy&#xD;
      and music therapy, or routine follow-up from the general practitioner. By its nature,&#xD;
      treatment group allocation cannot be blinded; however, both patients and therapists will be&#xD;
      blinded for end-point evaluation. An extensive investigational program will be carried out at&#xD;
      three time points: Prior to the intervention, immediately after the intervention, and 1 year&#xD;
      after the intervention. The program includes: Clinical examination; Pain threshold&#xD;
      assessment; Cardiovascular assessment; Cognitive assessment; Sampling of biological material&#xD;
      (blood and urine); Questionnaire; Brain fMRI; Qualitative interview; Monitoring of physical&#xD;
      activity (accelerometer)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physical activity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean steps/day during 7 consecutive days measured by accelerometer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma catecholamines</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma catecholamines</measure>
    <time_frame>64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine cortisol:creatinin ratio</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine cortisol:creatinin ratio</measure>
    <time_frame>64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree centrality index of cytokine network</measure>
    <time_frame>12 weeks</time_frame>
    <description>An index of node centrality, based upon network analyses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree centrality index of cytokine network</measure>
    <time_frame>64 weeks</time_frame>
    <description>An index of node centrality, based upon network analyses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of NK-cells</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of NK-cells</measure>
    <time_frame>64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supine heart rate</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supine heart rate</measure>
    <time_frame>64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability indices</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability indices</measure>
    <time_frame>64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate, blood pressure and total peripheral resistence responses to upright posture</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate, blood pressure and total peripheral resistence responses to upright posture</measure>
    <time_frame>64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Working memory</measure>
    <time_frame>12 weeks</time_frame>
    <description>Digit span forward and backward test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Working memory</measure>
    <time_frame>64 weeks</time_frame>
    <description>Digit span forward and backward test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive inhibition</measure>
    <time_frame>12 weeks</time_frame>
    <description>Color-word interference test from the D-KEFS instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive inhibition</measure>
    <time_frame>64 weeks</time_frame>
    <description>Color-word interference test from the D-KEFS instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation matrix indices of regions of interests (ROIs) in the brain salience network</measure>
    <time_frame>12 weeks</time_frame>
    <description>Functional connectivity analyses from resting state brain fMRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation matrix indices of regions of interests (ROIs) in the brain salience network</measure>
    <time_frame>64 weeks</time_frame>
    <description>Functional connectivity analyses from resting state brain fMRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue score (Chalder fatigue questionnaire)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue score (Chalder fatigue questionnaire)</measure>
    <time_frame>64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores (Brief pain Inventory)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores (Brief pain Inventory)</measure>
    <time_frame>64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life score (PedsQL)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life score (PedsQL)</measure>
    <time_frame>64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression score (HADS)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression score (HADS)</measure>
    <time_frame>64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alexithymia score (TAS-20)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alexithymia score (TAS-20)</measure>
    <time_frame>64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insomnia score (KSQ)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insomnia score (KSQ)</measure>
    <time_frame>64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain threshold (algometry)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain threshold (algometry)</measure>
    <time_frame>64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability score (FDI)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability score (FDI)</measure>
    <time_frame>64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effect and unexpected events questionnaire</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effect and unexpected events questionnaire</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effect and unexpected events questionnaire</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effect and unexpected events questionnaire</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>64 weeks</time_frame>
    <description>Mean steps/day during 7 consecutive days measured by accelerometer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Fatigue Syndrome, Chronic</condition>
  <condition>Epstein-Barr Virus Infection</condition>
  <arm_group>
    <arm_group_label>Mental training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention consists of one introductory session (patients and their parents/next-of-kin), followed by 9 individual therapy sessions (one each week) of 1.5 hours duration and related home-work, combining elements from cognitive behavioural therapy and music therapy: Important elements of the mental training program are:&#xD;
Psychoeducation: Theories of CFS/ME pathophysiology and treatment rationale&#xD;
Relaxation: Bodily stress reduction, mindfulness&#xD;
Visualization: Contact with positive emotions, techniques of worrying reduction&#xD;
Experiences: Behavioral 'experiments' (individually adjusted), 'trick into action'&#xD;
Cognitive challenges: Challenging thoughts about disease process, stimulus and outcome expectancies, prognosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine follow-up</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Routine follow-up by the general practitioner, which is normal approach to chronic fatigue following acute EBV infection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mental training</intervention_name>
    <arm_group_label>Mental training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant in the research project CEBA (Chronic fatigue following acute Epstein-Barr&#xD;
             virus infection in adolescents, NCT02335437)&#xD;
&#xD;
          -  Chronic fatigue at 6 months (a sum score of dichotomized responses ≥ 4 on the Chalder&#xD;
             Fatigue questionnaire)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other illnesses that might explain the fatigue&#xD;
&#xD;
          -  Bedridden&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vegard Bruun Wyller, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Akershus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Pediatrics, Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <state>Akershus</state>
        <zip>N-1478</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>July 9, 2015</study_first_submitted>
  <study_first_submitted_qc>July 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Akershus</investigator_affiliation>
    <investigator_full_name>Vegard Bruun Wyller, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Epstein-Barr Virus Infections</mesh_term>
    <mesh_term>Fatigue Syndrome, Chronic</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

